Practice Guidelines | |||
---|---|---|---|
AASLD10 | APASL11 | EASL12 | |
HBeAg-positive | ∙ HBV DNA >20,000 IU/mL ∙ ALT >2× ULN ∙ No spontaneous HBeAg seroconversion after 3–6 months' observation | ∙ HBV DNA ≥20,000 IU/mL ∙ ALT ≥2× ULN | ∙ HBV DNA >20,000 IU/mL ∙ ALT >2× ULN |
∙ HBV DNA >20,000 IU/mL ∙ ALT ≤2× ULN ∙ Moderate or worse liver inflammation or significant fibrosis (on biopsy*) | ∙ HBV DNA ≥20,000 IU/mL ∙ ALT ≥1 to <2× ULN ∙ Moderate or worse liver inflammation or fibrosis (on biopsy or noninvasive fibrosis assessment*) | ∙ HBV DNA >2000 IU/mL ∙ ALT >1× ULN ∙ Moderate or worse liver inflammation or moderate fibrosis (using a standardized scoring system†) | |
∙ HBV DNA >2000 IU/mL ∙ Cirrhosis | ∙ HBV DNA ≥2000 IU/mL ∙ Advanced fibrosis/cirrhosis | ∙ Detectable HBV DNA ∙ Cirrhosis | |
HBeAg-negative | ∙ HBV DNA >20,000 IU/mL ∙ ALT >2× ULN | ∙ HBV DNA ≥2000 IU/mL ∙ ALT >2× ULN | ∙ HBV DNA >20,000 IU/mL ∙ ALT >2× ULN |
∙ HBV DNA >2000 IU/mL ∙ ALT ≥1–2× ULN ∙ Moderate or worse liver inflammation or significant fibrosis (on biopsy) | ∙ HBV DNA ≥2000 IU/mL ∙ ALT ≥1 to <2× ULN ∙ Moderate or worse liver inflammation or fibrosis (on biopsy or noninvasive fibrosis assessment*) | ∙ HBV DNA >2000 IU/mL ∙ ALT >1× ULN ∙ Moderate or worse liver inflammation or moderate fibrosis | |
∙ HBV DNA >2000 IU/mL ∙ Cirrhosis | ∙ HBV DNA ≥2000 IU/mL ∙ Advanced fibrosis/cirrhosis | ∙ Detectable HBV DNA ∙ Cirrhosis |
↵* Assessment of liver disease is recommended if the patient is 40 years or older.
↵† Assessment of liver disease is recommended if the patient is 30 years or older. Biopsy is to be considered in patients of older age and/or with fluctuating/minimally elevated alanine aminotransferase (ALT) concentrations or family history of hepatocellular carcinoma.
AASLD, American Association for the Study of Liver Diseases; APASL, Asian Pacific Association for the Study of the Liver; EASL, European Association for the Study of the Liver; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ULN, upper limit of normal.